What one share of Biogen holds
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS.
Biogen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $67.35 |
|---|---|
| Profit | $9.30 |
| Capex (buildings and equipment) | $1.14 |
| Free cash flow | $16.42 |
| Cash and investments | $22.91 |
| Debt | $42.59 |
| Book value | $126.33 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2007 | $9.91 | $1.99 | $0.89 | $2.29 | — | $17.59 |
| 2008 | $13.89 | $2.65 | $0.94 | $4.36 | — | $20.16 |
| 2009 | $15.12 | $3.35 | $0.57 | $3.14 | — | — |
| 2010 | $18.51 | $3.94 | $0.68 | $5.70 | — | $22.44 |
| 2011 | $20.60 | $5.04 | $0.85 | $6.20 | — | $26.54 |
| 2012 | $23.01 | $5.76 | $1.06 | $6.78 | — | $29.43 |
| 2013 | $29.09 | $7.81 | $1.03 | $8.81 | — | $36.48 |
| 2014 | $40.91 | $12.37 | $1.21 | $11.19 | — | $46.07 |
| 2015 | $46.56 | $15.34 | $2.78 | $14.17 | — | $42.88 |
| 2016 | $52.33 | $16.92 | $2.82 | $18.15 | — | $56.23 |
| 2017 | $57.62 | $11.92 | $4.07 | $17.29 | — | $59.63 |
| 2018 | $65.53 | $21.58 | $3.75 | $26.39 | — | $66.12 |
| 2019 | $76.72 | $31.42 | $2.75 | $35.03 | — | $76.60 |
| 2020 | $83.35 | $24.80 | $2.63 | $23.59 | — | $70.21 |
| 2021 | $73.41 | $10.40 | $1.73 | $22.61 | — | $74.12 |
| 2022 | $69.68 | $20.87 | $1.65 | $7.84 | — | $93.04 |
| 2023 | $67.55 | $7.97 | $1.90 | $8.72 | — | $102.14 |
| 2024 | $66.32 | $11.19 | $1.05 | $18.66 | — | $114.65 |
| 2025 | $67.24 | $8.79 | $1.05 | $13.94 | — | $124.37 |
Common questions about Biogen
How much does one share of Biogen earn?
Over the last 12 months, each share of Biogen earned $9.30 of profit on $67.35 of sales, keeping about 14¢ of every $1 (profit margin).
Does Biogen pay a dividend?
Biogen didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Biogen’s book value per share?
Biogen’s book value is $126.33 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of March 31, 2026.
How much cash and debt does each share of Biogen have?
Each share of Biogen has $22.91 of cash and investments and $42.59 of debt, as of March 31, 2026.
What is Biogen’s free cash flow per share?
$16.42 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
How has Biogen’s profit per share changed over time?
Profit per share went from $1.99 in 2007 to $8.79 in 2025, growing about 8.6% a year (adjusted for stock splits).
Has Biogen bought back shares?
Biogen’s share count fell about 54% from 2007 to 2025. Through buybacks, each remaining share owns a bigger slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.